FLUIDDA is delighted to invite you to a dedicated session discussing her proprietary Functional Respiratory Imaging (FRI) technology and its application in drug and device development.
During the presentation FLUIDDA’s CEO, Dr. Jan De Backer, will present the technology and explain how it can be used to assess the potential of new respiratory drugs and devices. Some recent examples in Idiopathic Pulmonary Fibrosis (IPF) and Chronic Obstructive Pulmonary Disease (COPD) will be highlighted and an update on the regulatory status of FRI will provided.
The primary target audience for the session consists of market analysts and investors, however anyone with an interest in therapeutic development in respiratory medicine is welcome to register.
Kindly register by providing the following information, seating is limited: